Growth hormone considerations

Solo disponible en BuenasTareas
  • Páginas : 44 (10913 palabras )
  • Descarga(s) : 0
  • Publicado : 7 de febrero de 2011
Leer documento completo
Vista previa del texto
Growth Hormone: Health Considerations Beyond Height Gain Judith Ross, Paul Czernichow, Beverly M. K. Biller, Annamaria Colao, Ed Reiter, Wieland Kiess and on behalf of the participants in the advisory panel meeting on the effects of growth hormone Pediatrics 2010;125;e906-e918; originally published online Mar 22, 2010; DOI: 10.1542/peds.2009-1783

The online version of this article, along withupdated information and services, is located on the World Wide Web at: http://www.pediatrics.org/cgi/content/full/125/4/e906

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk GroveVillage, Illinois, 60007. Copyright © 2010 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

Downloaded from www.pediatrics.org. Provided by Chulalongkorn Univ on April 6, 2010

Growth Hormone: Health Considerations Beyond Height Gain abstract
The therapeutic benefit of growth hormone (GH) therapy in improving height in short childrenis widely recognized; however, GH therapy is associated with other metabolic actions that may be of benefit in these children. Beneficial effects of GH on body composition have been documented in several different patient populations as well as improvements in lipid profile. Marked augmentation of bone mineral density also seems evident in many pediatric populations. Some of these benefits may requirecontinued therapy past the acquisition of adult height. With long-term therapy of any kind, the adverse consequences of treatment should also be considered. Fortunately, long-term GH treatment seems to be safe and well-tolerated. This review describes the long-term metabolic effects of GH treatment in the pediatric population and considers how these may benefit children who are treated with GH.Pediatrics 2010;125:e906–e918
AUTHORS: Judith Ross, MD,a Paul Czernichow, MD,b Beverly M. K. Biller, MD,c Annamaria Colao, MD, PhD,d Ed Reiter, MD,e and Wieland Kiess, MD,f on behalf of the participants in the advisory panel meeting on the effects of growth hormone
Department of Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania; bDepartment of Pediatric Endocrinology andDiabetes, Necker-Enfants Malades Hopital, ˆ Paris, France; cDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts; dDepartment of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy; eDepartment of Pediatrics, Baystate Children’s Hospital, Springfield, Massachusetts; and fDepartment of Women and Child Health, Hospital for Children andAdolescents, University of Leipzig, Leipzig, Germany KEY WORDS growth hormone, body composition, metabolism, safety ABBREVIATIONS GH— growth hormone GHD— growth hormone deficiency LBM—lean body mass FM—fat mass QoL— quality of life BMD— bone mineral density SDS—SD score LDL-C—low-density lipoprotein cholesterol HDL-C— high-density lipoprotein cholesterol CVD— cardiovascular diseaseIGF-I—insulin-like growth factor I BMC— bone mineral content LV—left ventricular SGA—small for gestational age TS—Turner syndrome PWS—Prader-Willi syndrome ISS—idiopathic short stature IGFBP-3—insulin-like growth factor binding protein 3 CI— confidence interval www.pediatrics.org/cgi/doi/10.1542/peds.2009-1783 doi:10.1542/peds.2009-1783 Accepted for publication Nov 16, 2009 Address correspondence to Judith Ross, MD,Department of Pediatrics, Thomas Jefferson University, 1025 Walnut St, Suite 726, Philadelphia, PA 19107. E-mail: judith.ross@jefferson.edu PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2010 by the American Academy of Pediatrics FINANCIAL DISCLOSURE: All authors are members of the Global Norditropin Advisory Panel. Dr Reiter is a consultant for Novo Nordisk,...
tracking img